New drug aims to reduce bulging eyes in thyroid disease
NCT ID NCT07265258
First seen Jun 26, 2026 · Last updated Aug 14, 2026 · Updated 3 times
Summary
This study tests a new drug called teprotumumab N01 for active thyroid eye disease, which causes eye bulging and discomfort. About 92 adults will receive either the new drug or standard steroid treatment. The main goal is to see if the new drug better reduces eye bulging.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- teprotumumab N01
- What this could lead to
- If it works, this could offer a more effective treatment option for active thyroid eye disease, reducing eye bulging and double vision.
- What could go wrong
- This is a Phase 4 trial, but results may not show a clear advantage over existing steroid therapy. Side effects from the drug are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID EYE DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200125, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted antibody calm thyroid eye disease?
- Could a cholesterol drug shrink eye muscle swelling in thyroid eye disease?
- Can an experimental drug reduce eye bulging in thyroid eye disease?
- Can a new drug ease bulging eyes in thyroid disease?
- New drug IBI3031 enters first human trial for thyroid eye disease
- New hope for thyroid eye disease: drug shows promise in Steroid-Resistant patients